Kissei Pharmaceutical Co Ltd (4547.T)

4547.T on Tokyo Stock Exchange

19 Mar 2018
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

JR-131, long-acting erythropoiesis-stimulating agent, demonstrates equivalence in phase III study
Wednesday, 17 Jan 2018 

Jan 17 (Reuters) - Kissei Pharmaceutical Co Ltd <4547.T>:Says it and JCR Pharmaceuticals Co Ltd <<<4552.T>>> jointly announced positive results of the phase III study for JR-131, a proposed biosimilar to darbepoetin alfa, a long-acting erythropoiesis-stimulating agent for the treatment of renal anemia .In the Phase III study initiated in August 2016, JR-131 demonstrated equivalence in efficacy and safety compared with darbepoetin.Accordingly, in a primary endpoint of efficacy, the equivalence was verified for variations in hemoglobin concentration and the similarity with regard to the safety profile was confirmed .  Full Article

Kyorin and KISSEI sign agreement for co-development and co-marketing of KRP-114V
Wednesday, 30 Mar 2016 

Kyorin Holdings Inc:KYORIN Pharmaceutical Co., Ltd., a wholly-owned subsidiary of KYORIN Holdings, Inc. and Kissei Pharmaceutical Co., Ltd. jointly announced a co-development and co-marketing agreement for an overactive bladder medication of KRP-114V (INN: Vibegron) which is being developed by Kyorin in Japan.  Full Article

BRIEF-Kissei Pharmaceutical completes share repurchase

* Says it completed repurchase of 1.6 million shares of its common stock, for 4.46 billion yen in total, through ToSTNeT-3, on Feb. 13